Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CSL 112

Next Previous
X
Search
Drug Profile

CSL 112

Alternative Names: ApoA-1; Apolipoprotein A-I - CSL Behring; CSL-112; CSL112 (reconstituted HDL) - CSL; CSL112 apo-AI; rHDL - CSL

Latest Information Update: 13 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL
  • Class Anti-ischaemics; Lipoproteins; Recombinant proteins; Vascular disorder therapies
  • Mechanism of Action Apolipoprotein A-I replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myocardial infarction
  • Discontinued Atherosclerosis

Most Recent Events

  • 11 Feb 2024 Efficacy and adverse events data from a phase III AEGIS trial in Myocardial infarction released by CSL
  • 25 Aug 2023 Efficacy data from phase II trial in Myocardial infarction presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology (ESC-Card-2023)
  • 16 Feb 2023 CSL completes a phase III trial in Myocardial infarction in Argentina, Belgium, Brazil, Chile, Colombia, Croatia, Estonia, Finland, Greece, Hong Kong, South Korea, Latvia, Lithuania, Malaysia, Mexico, New Zealand, Norway, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, Spain, Poland, Netherlands, Italy, Israel, Hungary, Germany, France, Denmark, Czech Republic, Canada, Bulgaria, Austria, Australia, Japan, Georgia and Peru (IV) (NCT03473223; EudraCT-2017-000996-98)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top